AbbVie Inc (ABBV)vsUltragenyx (RARE)
ABBV
AbbVie Inc
$291.27
+1.05%
HEALTHCARE · Cap: $521.11B
RARE
Ultragenyx
$15.57
-9.27%
HEALTHCARE · Cap: $1.65B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 9107% more annual revenue ($66.01B vs $717.00M). ABBV leads profitability with a 15.7% profit margin vs -81.7%. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
RARE
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.0%
Fair Value
$156.84
Current Price
$291.27
$134.43 premium
Intrinsic value data unavailable for RARE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Conservative balance sheet, low leverage
Revenue surging 28.1% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -608.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : RARE
The strongest argument for RARE centers on Debt/Equity, Revenue Growth. Revenue growth of 28.1% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : RARE
The primary concerns for RARE are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a mature stock while RARE is a growth play — different risk/reward profiles.
RARE carries more volatility with a beta of 0.35 — expect wider price swings.
RARE is growing revenue faster at 28.1% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 31/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Ultragenyx
HEALTHCARE · BIOTECHNOLOGY · USA
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is headquartered in Novato, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?